Skip to main content

Table 4 The comparison and outcome analyses of the patients with monotherapy of tigecycline or sulbactam

From: Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex

Variables

TG groupa

SB groupa

p

Deceasedab

Survivorsa

p

n = 39

n = 13

 

n = 11

n = 41

 

Demographic parameters

 Age, yr

71.4 (15.0)

68.7 (19.9)

0.899

75.3 (12.0)

69.5 (17.1)

0.439

 Male gender

25 (64.1)

10 (76.9)

0.506

8 (72.7)

27 (65.9)

1.000

Concomitant diseases

 Hepatic dysfunction

3 (7.7)

0 (0.0)

0.564

1 (9.1)

2 (4.9)

0.518

 Renal insufficiency

10 (25.6)

4 (30.8)

0.729

1 (9.1)

13 (31.7)

0.251

 Chronic pulmonary disease

11 (28.2)

4 (30.8)

1.000

4 (36.4)

11 (26.8)

0.709

 Heart disease

6 (15.4)

1 (7.7)

0.664

2 (18.2)

5 (12.2)

0.630

 Diabetes mellitus

9 (23.1)

4 (30.8)

0.714

3 (27.3)

10 (24.4)

1.000

 Immune compromise

8 (20.5)

1 (7.7)

0.420

2 (18.2)

7 (17.1)

1.000

 Malignancy

8 (20.5)

3 (23.1)

1.000

4 (36.4)

7 (17.1)

0.216

Surgery

9 (23.1)

1 (7.7)

0.419

2 (18.2)

8 (19.5)

1.000

Clinical conditions

 APACHE II Score

17.0 (6.1)

18.2 (6.0)

0.557

17.1 (6.8)

17.3 (5.9)

0.904

 Ventilator use

21 (53.8)

11 (84.6)

0.048

6 (54.5)

26 (63.4)

0.730

 Bilateral pneumonia

18 (46.2)

12 (92.3)

0.004

8 (72.7)

22 (53.7)

0.319

 Polymicrobial pneumonia

31 (79.5)

9 (69.2)

0.466

9 (81.8)

31 (75.6)

1.000

  With MRSA

20 (51.3)

6 (46.2)

0.749

5 (45.5)

21 (51.2)

0.734

  With Pseudomonas aeruginosa

14 (35.9)

3 (23.1)

0.506

5 (45.5)

12 (29.3)

0.470

  With Klebsiella spp.

7 (17.9)

1 (7.7)

0.662

1 (9.1)

7 (17.1)

1.000

  With Serratia marcescens

5 (12.8)

1 (7.7)

1.000

1 (9.1)

5 (12.2)

1.000

  With Stenotrophomanas maltophilia

3 (7.7)

3 (23.1)

0.157

1 (9.1)

5 (12.2)

1.000

 Multisite infections

14 (35.9)

5 (38.5)

1.000

4 (36.4)

15 (36.6)

1.000

  With urinary tract infection

7 (17.9)

3 (23.1)

0.697

2 (18.2)

8 (19.5)

1.000

  With catheter related infection

0 (0.0)

2 (15.4)

0.059

1 (9.1)

1 (2.4)

0.382

  With skin and soft tissue infection

3 (7.7)

1 (7.7)

1.000

1 (9.1)

3 (7.3)

1.000

  With intra-abdominal infection

4 (10.3)

0 (0.0)

0.561

0 (0.0)

4 (9.8)

0.567

  With invasive fungal infection

6 (15.4)

0 (0.0)

0.317

1 (9.1)

5 (12.2)

1.000

Microbiology

 MDR Acb complex with TG or SB resistancec

6 (15.4)

4 (30.8)

0.244

1 (9.1)

9 (22.0)

0.668

 Airway eradication of MDR Acb complexd

12 (34.3)

8 (88.9)

0.006

4 (57.1)

16 (43.2)

0.684

 Bacteremia during treatment

2 (5.1)

0 (0.0)

1.000

1 (9.1)

1 (2.4)

0.382

Treatment

 Tigecycline-based treatment

   

7 (63.6)

32 (78.0)

0.435

 Duration, days

13.8 (5.1)

12.7 (5.6)

0.293

11.9 (3.0)

14.0 (5.6)

0.398

 Delayed treatment

20 (51.3)

5 (38.5)

0.423

5 (45.5)

20 (48.8)

0.845

Outcomes

 Clinical resolution of pneumonia

26 (66.7)

8 (61.5)

0.747

   

 Mortality during treatment

7 (17.9)

4 (30.8)

0.435

   

 30-day mortality

10 (25.6)

7 (53.8)

0.089

   
  1. Abbreviations: TG tigecycline, SB sulbactam, APACHE acute physiology and chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii
  2. aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)
  3. bMortality during treatment
  4. cThe initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
  5. d35 patients in TG group and 9 in SB group; 7 patients in the deceased group and 37 in the survivors group had available data for evaluation
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us